Key takeaway: PDUFA enables the FDA to collect user fees from the biopharmaceutical industry, allowing for efficient and more predictable reviews. This funding model […]
What is PDUFA—and why does it matter for biotech innovators, FDA & patients? Read More »
When a biotech firm sells investors on the promise of a new drug, what they are really selling is the intellectual property behind their
BIO is expanding its work to defend IP Read More »
Since its founding in 1920, the National Health Council (NHC) has brought diverse organizations together to forge consensus and drive patient-centered health policy in
Q&A with National Health Council: Driving patient-centred policy Read More »
“Biotechnology innovation is advancing at an unprecedented pace, delivering new treatments and cures that offer long-awaited hope to patients and their families,” said Karin
BIO Coffee Chat: Price controls like MFN harm access, increase costs Read More »
Strong intellectual property protections sustain biotechnology innovation by enabling the investment needed to develop new medical breakthroughs. In comments submitted for the 2026 U.S.
BIO’s comments for USTR report highlight global threats to intellectual property Read More »
A year after a congressional commission urged strategic action to prevent China from replacing America as the world leader in biotechnology, we still have
BIO CEO hails congressional report on threat of China dominating biotech Read More »
The inaugural BIO Investment and Growth (BIG) Summit was a chance for leaders in the biotech industry to catch up on domestic and international
BIG Summit themes: Resilient investment, MFN threat, patients in the center Read More »
Washington’s healthcare policy landscape is constantly evolving, and 2026 is shaping up to be another consequential year for the biotech industry. Some developments are
BIG Summit panel breaks down risks and opportunities coming out of DC Read More »
With health care affordability a top concern for many Americans, pharmacy benefit managers (PBMs) continue to stand at the center of the debate. Working
The hidden layer of PBMs: What a recent investigation reveals Read More »
Americans are frustrated with the health care system for two reasons. First, it costs too much. But—second—it provides too little. While most of the
Nearly half of Americans say insurers’ rules on access delayed, denied, or altered care Read More »
